摘要
目的 :观察干扰素治疗慢性粒细胞白血病的疗效。方法 :应用基因重组α干扰素 (IFN α)治疗 31例慢性粒细胞白血病 (CML) ,其中慢性期 (CP) 30例 ,(1例完全缓解病例 ) ,加速期 (AP) 1例。剂量为隔日 30 0万U平均疗程为 9个月 (3～ 4 0个月 )。结果 :单用IFN α治疗CMLCP 5例 ,其中 2例有效 ;联用甲异靛治疗 12例 ,联用羟基脲治疗 14例 ,有效率分别为 91.6 %和 5 7.1% ,与单用甲异靛或羟基脲治疗相比无显著差异。缓解后有 8例单用IFN α维持治持 ,平均持续缓解时间为 6个月。复查Ph+ CML 16例 ,治疗后均未达到完全转阴。结论 :提示IFN α可用于CMLCP和缓解后维持治疗 ,若加大剂量和延长用药时间 ,有可能进一步提高疗效。IFN
Objective:To evaluate the effect of recombinant interferon-α(rIFN-α)for chornic myelocytic leukemia (CML). Methods: 31 cases of CML, including 30 with chronic phase (CP) in whom one with complete remission (CR) and one with accelerated phase (AP), were treated with rIFN-α. The usage was 3×10 6 unit every other day and the average course was nine-month (3-40 month). Results: 5 patients received rIFN-α alone, 12 received rIFN-α plus meisoindigo, and 14 received rIFN-α plus hydroxyures. The response rates were 40%, 91.6%, and 57.1% respectively. Compared with the patients receiving meisoindigo or hydroxyurea alone there was no significant difference. After remission there were 8 patients receiving maintenance treatment and the average remission duration was 6 month. 16 patients were tested for Ph cell after treatment and non of them showed negative Ph. Conclusions:This research indicate that rIFM-α can be used for patients with CML CP and maintenance treatment after remission. It may be possible that the effect is improved if the dosage is increased and the course is extended. There is no response by using rIFN-α for CML AP.
出处
《江汉大学学报（自然科学版）》
2004年第2期55-57,共3页
Journal of Jianghan University：Natural Science Edition
